Current and Past Immunodeficiency Are Associated With Higher Hospitalization Rates Among Persons on Virologically Suppressive Antiretroviral Therapy for up to 11 Years.


Journal

The Journal of infectious diseases
ISSN: 1537-6613
Titre abrégé: J Infect Dis
Pays: United States
ID NLM: 0413675

Informations de publication

Date de publication:
16 08 2021
Historique:
received: 24 08 2020
accepted: 22 12 2020
entrez: 16 8 2021
pubmed: 17 8 2021
medline: 2 2 2022
Statut: ppublish

Résumé

Persons with human immunodeficiency virus (PWH) with persistently low CD4 counts despite efficacious antiretroviral therapy could have higher hospitalization risk. In 6 US and Canadian clinical cohorts, PWH with virologic suppression for ≥1 year in 2005-2015 were followed until virologic failure, loss to follow-up, death, or study end. Stratified by early (years 2-5) and long-term (years 6-11) suppression and lowest presuppression CD4 count <200 and ≥200 cells/µL, Poisson regression models estimated hospitalization incidence rate ratios (aIRRs) comparing patients by time-updated CD4 count category, adjusted for cohort, age, gender, calendar year, suppression duration, and lowest presuppression CD4 count. The 6997 included patients (19 980 person-years) were 81% cisgender men and 40% white. Among patients with lowest presuppression CD4 count <200 cells/μL (44%), patients with current CD4 count 200-350 vs >500 cells/μL had aIRRs of 1.44 during early suppression (95% confidence interval [CI], 1.01-2.06), and 1.67 (95% CI, 1.03-2.72) during long-term suppression. Among patients with lowest presuppression CD4 count ≥200 (56%), patients with current CD4 351-500 vs >500 cells/μL had an aIRR of 1.22 (95% CI, .93-1.60) during early suppression and 2.09 (95% CI, 1.18-3.70) during long-term suppression. Virologically suppressed patients with lower CD4 counts experienced higher hospitalization rates and could potentially benefit from targeted clinical management strategies.

Sections du résumé

BACKGROUND
Persons with human immunodeficiency virus (PWH) with persistently low CD4 counts despite efficacious antiretroviral therapy could have higher hospitalization risk.
METHODS
In 6 US and Canadian clinical cohorts, PWH with virologic suppression for ≥1 year in 2005-2015 were followed until virologic failure, loss to follow-up, death, or study end. Stratified by early (years 2-5) and long-term (years 6-11) suppression and lowest presuppression CD4 count <200 and ≥200 cells/µL, Poisson regression models estimated hospitalization incidence rate ratios (aIRRs) comparing patients by time-updated CD4 count category, adjusted for cohort, age, gender, calendar year, suppression duration, and lowest presuppression CD4 count.
RESULTS
The 6997 included patients (19 980 person-years) were 81% cisgender men and 40% white. Among patients with lowest presuppression CD4 count <200 cells/μL (44%), patients with current CD4 count 200-350 vs >500 cells/μL had aIRRs of 1.44 during early suppression (95% confidence interval [CI], 1.01-2.06), and 1.67 (95% CI, 1.03-2.72) during long-term suppression. Among patients with lowest presuppression CD4 count ≥200 (56%), patients with current CD4 351-500 vs >500 cells/μL had an aIRR of 1.22 (95% CI, .93-1.60) during early suppression and 2.09 (95% CI, 1.18-3.70) during long-term suppression.
CONCLUSIONS
Virologically suppressed patients with lower CD4 counts experienced higher hospitalization rates and could potentially benefit from targeted clinical management strategies.

Identifiants

pubmed: 34398239
pii: 6053002
doi: 10.1093/infdis/jiaa786
pmc: PMC8366443
doi:
pii:

Substances chimiques

Anti-HIV Agents 0

Types de publication

Journal Article Research Support, N.I.H., Extramural Research Support, N.I.H., Intramural Research Support, Non-U.S. Gov't Research Support, U.S. Gov't, P.H.S.

Langues

eng

Sous-ensembles de citation

IM

Pagination

657-666

Subventions

Organisme : NIDA NIH HHS
ID : F31 DA037788
Pays : United States
Organisme : NIDA NIH HHS
ID : K24 DA000432
Pays : United States
Organisme : NIAID NIH HHS
ID : P30 AI110527
Pays : United States
Organisme : NHLBI NIH HHS
ID : U01 HL146241
Pays : United States
Organisme : NHLBI NIH HHS
ID : U01 HL146193
Pays : United States
Organisme : NIDA NIH HHS
ID : R01 DA012568
Pays : United States
Organisme : NIAAA NIH HHS
ID : U01 AA020790
Pays : United States
Organisme : NIAID NIH HHS
ID : U01 AI068636
Pays : United States
Organisme : NIMH NIH HHS
ID : P30 MH062246
Pays : United States
Organisme : NEI NIH HHS
ID : U10 EY008057
Pays : United States
Organisme : NIAID NIH HHS
ID : T32 AI007001
Pays : United States
Organisme : CIHR
ID : TGF-96118
Pays : Canada
Organisme : NIAID NIH HHS
ID : U01 AI038855
Pays : United States
Organisme : NIAID NIH HHS
ID : P30 AI050410
Pays : United States
Organisme : NHLBI NIH HHS
ID : U01 HL146194
Pays : United States
Organisme : NIAID NIH HHS
ID : U01 AI069432
Pays : United States
Organisme : NIA NIH HHS
ID : R01 AG053100
Pays : United States
Organisme : NIAID NIH HHS
ID : F31 AI124794
Pays : United States
Organisme : NHLBI NIH HHS
ID : U01 HL146202
Pays : United States
Organisme : NIAAA NIH HHS
ID : U24 AA020794
Pays : United States
Organisme : NIMHD NIH HHS
ID : G12 MD007583
Pays : United States
Organisme : NCATS NIH HHS
ID : UL1 TR001863
Pays : United States
Organisme : NEI NIH HHS
ID : U10 EY008052
Pays : United States
Organisme : NHLBI NIH HHS
ID : U01 HL146245
Pays : United States
Organisme : CIHR
ID : CBR-94036
Pays : Canada
Organisme : NHLBI NIH HHS
ID : U01 HL146205
Pays : United States
Organisme : NIDA NIH HHS
ID : U01 DA036935
Pays : United States
Organisme : NIAAA NIH HHS
ID : U01 AA013566
Pays : United States
Organisme : NEI NIH HHS
ID : U10 EY008067
Pays : United States
Organisme : NIAID NIH HHS
ID : K01 AI093197
Pays : United States
Organisme : NIMHD NIH HHS
ID : U54 MD007587
Pays : United States
Organisme : NIAID NIH HHS
ID : P30 AI027767
Pays : United States
Organisme : NHLBI NIH HHS
ID : U01 HL146333
Pays : United States
Organisme : NIAID NIH HHS
ID : U01 AI038858
Pays : United States
Organisme : NIDA NIH HHS
ID : R01 DA011602
Pays : United States
Organisme : NIAID NIH HHS
ID : K24 AI065298
Pays : United States
Organisme : NHLBI NIH HHS
ID : U01 HL146242
Pays : United States
Organisme : NIAID NIH HHS
ID : P30 AI027757
Pays : United States
Organisme : NIAID NIH HHS
ID : K24 AI118591
Pays : United States
Organisme : NHLBI NIH HHS
ID : U01 HL146204
Pays : United States
Organisme : NIAID NIH HHS
ID : U01 AI069434
Pays : United States
Organisme : NIAID NIH HHS
ID : U01 AI068634
Pays : United States
Organisme : CIHR
ID : HCP-97105
Pays : Canada
Organisme : NIAID NIH HHS
ID : K01 AI131895
Pays : United States
Organisme : NHLBI NIH HHS
ID : U01 HL146192
Pays : United States
Organisme : NCATS NIH HHS
ID : UL1 TR000083
Pays : United States
Organisme : NIAID NIH HHS
ID : P30 AI027763
Pays : United States
Organisme : NIAAA NIH HHS
ID : R01 AA016893
Pays : United States
Organisme : CIHR
ID : CBR-86906
Pays : Canada
Organisme : NHLBI NIH HHS
ID : U01 HL146208
Pays : United States
Organisme : NIAID NIH HHS
ID : U01 AI069918
Pays : United States
Organisme : NCRR NIH HHS
ID : UL1 RR024131
Pays : United States
Organisme : NIDA NIH HHS
ID : T32 DA007250
Pays : United States
Organisme : NIAID NIH HHS
ID : P30 AI050409
Pays : United States
Organisme : Intramural NIH HHS
ID : Z01 CP010124
Pays : United States
Organisme : NHLBI NIH HHS
ID : U01 HL146201
Pays : United States
Organisme : NHLBI NIH HHS
ID : U01 HL146203
Pays : United States
Organisme : NCI NIH HHS
ID : N01 CP001004
Pays : United States
Organisme : NHLBI NIH HHS
ID : U01 HL146240
Pays : United States
Organisme : NEI NIH HHS
ID : K23 EY013707
Pays : United States
Organisme : NIAID NIH HHS
ID : P30 AI094189
Pays : United States
Organisme : NCATS NIH HHS
ID : UL1 TR000004
Pays : United States
Organisme : Intramural NIH HHS
ID : Z01 CP010176
Pays : United States
Organisme : NCATS NIH HHS
ID : KL2 TR000421
Pays : United States
Organisme : NIAID NIH HHS
ID : P30 AI036219
Pays : United States
Organisme : NIAID NIH HHS
ID : R24 AI067039
Pays : United States

Investigateurs

Constance A Benson (CA)
Ronald J Bosch (RJ)
Gregory D Kirk (GD)
Kenneth H Mayer (KH)
Chris Grasso (C)
Robert S Hogg (RS)
Julio S G Montaner (JSG)
Kate Salters (K)
Viviane D Lima (VD)
Paul Sereda (P)
Jason Trigg (J)
Kate Buchacz (K)
Jun Li (J)
Kelly A Gebo (KA)
Richard D Moore (RD)
Richard D Moore (RD)
Benigno Rodriguez (B)
Michael A Horberg (MA)
Michael J Silverberg (MJ)
Jennifer E Thorne (JE)
Todd Brown (T)
Phyllis Tien (P)
Gypsyamber D'Souza (G)
Charles Rabkin (C)
Marina B Klein (MB)
Abigail Kroch (A)
Ann Burchell (A)
Adrian Betts (A)
Oanne Lindsay (O)
Robert F Hunter-Mellado (RF)
Angel M Mayor (AM)
M John Gill (MJ)
Jeffrey N Martin (JN)
Jun Li (J)
John T Brooks (JT)
Michael S Saag (MS)
Michael J Mugavero (MJ)
James Willig (J)
William C Mathews (WC)
Joseph J Eron (JJ)
Sonia Napravnik (S)
Mari M Kitahata (MM)
Heidi M Crane (HM)
Timothy R Sterling (TR)
David Haas (D)
Peter Rebeiro (P)
Megan Turner (M)
Janet Tate (J)
Robert Dubrow (R)
David Fiellin (D)
Richard D Moore (RD)
Keri N Althoff (KN)
Stephen J Gange (SJ)
Mari M Kitahata (MM)
Michael S Saag (MS)
Michael A Horberg (MA)
Marina B Klein (MB)
Rosemary G McKaig (RG)
Aimee M Freeman (AM)
Richard D Moore (RD)
Keri N Althoff (KN)
Aimee M Freeman (AM)
Mari M Kitahata (MM)
Stephen E Van Rompaey (SE)
Heidi M Crane (HM)
Liz Morton (L)
Justin McReynolds (J)
William B Lober (WB)
Stephen J Gange (SJ)
Keri N Althoff (KN)
Jennifer S Lee (JS)
Bin You (B)
Brenna Hogan (B)
Jinbing Zhang (J)
Jerry Jing (J)
Elizabeth Humes (E)
Lucas Gerace (L)
Sally Coburn (S)

Informations de copyright

© The Author(s) 2020. Published by Oxford University Press for the Infectious Diseases Society of America. All rights reserved. For permissions, e-mail: journals.permissions@oup.com.

Références

Ann Intern Med. 2008 Dec 16;149(12):854-60
pubmed: 19075204
J Infect Dis. 2016 Oct 1;214 Suppl 2:S44-50
pubmed: 27625430
Clin Infect Dis. 2015 Mar 15;60(6):941-9
pubmed: 25409471
Am J Hypertens. 2017 Jun 1;30(6):594-601
pubmed: 28407044
Int J Epidemiol. 2007 Apr;36(2):294-301
pubmed: 17213214
JAMA Oncol. 2020 Feb 1;6(2):227-235
pubmed: 31804663
J Virol. 2003 Nov;77(21):11708-17
pubmed: 14557656
N Engl J Med. 2013 Jan 17;368(3):218-30
pubmed: 23323898
JAMA. 2016 Jun 21;315(23):2542-53
pubmed: 27327801
J Acquir Immune Defic Syndr. 2003 Oct 1;34(2):165-73
pubmed: 14526205
J Infect Dis. 2020 Jul 9;222(Suppl 1):S8-S19
pubmed: 32645162
J Acquir Immune Defic Syndr. 2014 Feb 1;65(2):160-6
pubmed: 24442222
J Infect Dis. 2005 Feb 1;191(3):348-57
pubmed: 15633093
Clin Infect Dis. 2020 Apr 15;70(9):1985-1992
pubmed: 31209457
Clin Infect Dis. 2021 Jun 15;72(12):2079-2086
pubmed: 32271361
J Acquir Immune Defic Syndr. 2010 Mar;53(3):397-404
pubmed: 19841589
Clin Infect Dis. 2020 Oct 23;71(7):1616-1623
pubmed: 31637434
Clin Infect Dis. 2020 Aug 11;:
pubmed: 32780095
J Int AIDS Soc. 2016 Mar 07;19(1):20524
pubmed: 26955965
J Infect Dis. 2015 Jun 1;211(11):1692-702
pubmed: 25512624
AIDS. 2018 Jan 14;32(2):261-266
pubmed: 29112076
HIV Med. 2019 Feb;20(2):110-120
pubmed: 30430742
AIDS. 2008 Jul 11;22(11):1345-54
pubmed: 18580614
Ann Intern Med. 2018 Sep 18;169(6):376-384
pubmed: 30140916
Cancer Epidemiol Biomarkers Prev. 2011 Dec;20(12):2551-9
pubmed: 22109347
AIDS. 2018 Nov 13;32(17):2605-2614
pubmed: 30289817
J Acquir Immune Defic Syndr. 2012 Apr 1;59(4):368-75
pubmed: 22240460
Clin Infect Dis. 2020 Jun 24;71(1):41-50
pubmed: 31634398
Clin Infect Dis. 2013 Jul;57(2):314-21
pubmed: 23575194
AIDS Patient Care STDS. 2014 Dec;28(12):613-21
pubmed: 25329710
Health Place. 2016 Nov;42:148-158
pubmed: 27770671
Ann Intern Med. 2015 Mar 3;162(5):335-44
pubmed: 25732274
AIDS Care. 2020 Nov;32(11):1353-1362
pubmed: 31813269
Clin Infect Dis. 2018 Apr 3;66(8):1230-1238
pubmed: 29149237
HIV Med. 2010 May;11(5):289-98
pubmed: 20002778
J Antimicrob Chemother. 2016 Sep;71(9):2654-62
pubmed: 27330061
J Infect Dis. 2021 Jun 15;223(12):2113-2123
pubmed: 33084891
AIDS Behav. 2016 May;20(5):967-72
pubmed: 26542730
J Infect Dis. 2016 Sep 15;214(6):862-72
pubmed: 27559122

Auteurs

Thibaut Davy-Mendez (T)

Gillings School of Global Public Health, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, USA.
School of Medicine, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, USA.

Sonia Napravnik (S)

Gillings School of Global Public Health, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, USA.
School of Medicine, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, USA.

Joseph J Eron (JJ)

Gillings School of Global Public Health, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, USA.
School of Medicine, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, USA.

Stephen R Cole (SR)

Gillings School of Global Public Health, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, USA.

David van Duin (D)

School of Medicine, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, USA.

David A Wohl (DA)

Gillings School of Global Public Health, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, USA.
School of Medicine, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, USA.

Brenna C Hogan (BC)

Bloomberg School of Public Health, Johns Hopkins University, Baltimore, Maryland, USA.

Keri N Althoff (KN)

Bloomberg School of Public Health, Johns Hopkins University, Baltimore, Maryland, USA.
School of Medicine, Johns Hopkins University, Baltimore, Maryland, USA.

Kelly A Gebo (KA)

Bloomberg School of Public Health, Johns Hopkins University, Baltimore, Maryland, USA.
School of Medicine, Johns Hopkins University, Baltimore, Maryland, USA.

Richard D Moore (RD)

Bloomberg School of Public Health, Johns Hopkins University, Baltimore, Maryland, USA.
School of Medicine, Johns Hopkins University, Baltimore, Maryland, USA.

Michael J Silverberg (MJ)

Kaiser Permanente Northern California, Oakland, California, USA.

Michael A Horberg (MA)

Kaiser Permanente Mid-Atlantic Permanente Research Institute, Rockville, Maryland, USA.

M John Gill (MJ)

Southern Alberta HIV Clinic, Calgary, Alberta, Canada.

W Christopher Mathews (WC)

School of Medicine, University of California, San Diego, San Diego, California, USA.

Marina B Klein (MB)

Faculty of Medicine, McGill University, Montreal, Quebec, Canada.

Jonathan A Colasanti (JA)

School of Medicine, Emory University, Atlanta, Georgia, USA.

Timothy R Sterling (TR)

School of Medicine, Vanderbilt University, Nashville, Tennessee, USA.

Angel M Mayor (AM)

School of Medicine, Universidad Central del Caribe, Bayamon, Puerto Rico, USA.

Peter F Rebeiro (PF)

School of Medicine, Vanderbilt University, Nashville, Tennessee, USA.

Kate Buchacz (K)

Division of HIV/AIDS Prevention, Centers for Disease Control and Prevention, Atlanta, Georgia, USA.

Jun Li (J)

Division of HIV/AIDS Prevention, Centers for Disease Control and Prevention, Atlanta, Georgia, USA.

Ni Gusti Ayu Nanditha (NGA)

Faculty of Medicine, University of British Columbia, Vancouver, British Columbia, Canada.

Jennifer E Thorne (JE)

School of Medicine, Johns Hopkins University, Baltimore, Maryland, USA.

Ank Nijhawan (A)

University of Texas Southwestern Medical Center, Dallas, Texas, USA.

Stephen A Berry (SA)

School of Medicine, Johns Hopkins University, Baltimore, Maryland, USA.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH